留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

类风湿关节炎患者血清KL-6和IL-33的表达水平及其临床意义

黄月 魏小松 江超 吴汉霞 王涛 李志军

黄月, 魏小松, 江超, 吴汉霞, 王涛, 李志军. 类风湿关节炎患者血清KL-6和IL-33的表达水平及其临床意义[J]. 中华全科医学, 2023, 21(11): 1856-1859. doi: 10.16766/j.cnki.issn.1674-4152.003242
引用本文: 黄月, 魏小松, 江超, 吴汉霞, 王涛, 李志军. 类风湿关节炎患者血清KL-6和IL-33的表达水平及其临床意义[J]. 中华全科医学, 2023, 21(11): 1856-1859. doi: 10.16766/j.cnki.issn.1674-4152.003242
HUANG Yue, WEI Xiaosong, JIANG Chao, WU Hanxia, WANG Tao, LI Zhijun. Expression levels of serum Krebs von den Lungen-6 and interleukin 33 in rheumatoid arthritis patients and their clinical significance[J]. Chinese Journal of General Practice, 2023, 21(11): 1856-1859. doi: 10.16766/j.cnki.issn.1674-4152.003242
Citation: HUANG Yue, WEI Xiaosong, JIANG Chao, WU Hanxia, WANG Tao, LI Zhijun. Expression levels of serum Krebs von den Lungen-6 and interleukin 33 in rheumatoid arthritis patients and their clinical significance[J]. Chinese Journal of General Practice, 2023, 21(11): 1856-1859. doi: 10.16766/j.cnki.issn.1674-4152.003242

类风湿关节炎患者血清KL-6和IL-33的表达水平及其临床意义

doi: 10.16766/j.cnki.issn.1674-4152.003242
基金项目: 

安徽省卫生健康软科学研究项目 2020WR03013

详细信息
    通讯作者:

    李志军,E-mail:lizhijundr@126.com

  • 中图分类号: R593.22

Expression levels of serum Krebs von den Lungen-6 and interleukin 33 in rheumatoid arthritis patients and their clinical significance

  • 摘要:   目的  了解类风湿关节炎(RA)患者血清涎液化糖链抗原6(KL-6)和白细胞介素33(IL-33)的表达水平,探讨检测血清KL-6和IL-33对RA相关间质性肺病(RA-ILD)的诊断价值。  方法  选择2022年5月—2023年2月在蚌埠医学院第一附属医院和安徽理工大学第一附属医院风湿科住院并确诊为RA的患者88例,根据肺部CT有无间质性肺病(ILD)分为一般RA组(40例)和RA-ILD组(48例)。所有患者均检测与RA相关的血清学指标,如血清类风湿因子(RF)、红细胞沉降率(ESR)和抗环瓜氨酸肽抗体(抗CCP抗体)等。同时检测上述患者血清KL-6和IL-33水平,分析各项指标与ILD的相关性,通过受试者工作特征(ROC)曲线分析各指标对RA-ILD的诊断效能。  结果  RA-ILD组患者血清KL-6、IL-33水平显著升高;血清KL-6与ESR、CRP、D-二聚体呈正相关关系,血清IL-33与IgG、球蛋白呈正相关关系。经ROC曲线分析发现,各项指标(RF、ESR、CRP、D-二聚体、IgA、KL-6、IL-33)诊断RA-ILD的曲线下面积(AUC)分别为0.678、0.667、0.716、0.702、0.666、0.773和0.705。KL-6、IL-33联合检测诊断RA-ILD的AUC为0.816,均优于各项单独检测。  结论  联合检测RA患者血清KL-6和IL-33,对RA-ILD的早期诊断及病情严重性判断有较高的参考价值。

     

  • 图  1  各项血清免疫学指标的ROC曲线

    注: A为RF、ESR、CRP、IgA、D-二聚体、KL-6和IL-33各项指标单独应用; B为KL-6、IL-33指标联合应用。

    Figure  1.  ROC curves of various serum immunological indices

    表  1  2组RA患者关节表现情况比较[例(%)]

    Table  1.   Comparison of joint performance between two groups of RA patients [cases(%)]

    组别 例数 多关节受累 寡关节受累 单关节受累 无关节压痛
    一般RA组 40 23(57.5) 9(22.5) 2(5.0) 6(15.0)
    RA-ILD组 48 30(62.4) 9(18.8) 2(4.2) 7(14.6)
    注:寡关节受累指受累关节数2~4个,多关节受累指受累关节数≥5个。2组关节表现情况比较,Z=0.496, P=0.620。
    下载: 导出CSV

    表  2  2组RA患者实验室检测结果比较

    Table  2.   Comparison of laboratory test results between two groups of RA patients

    组别 例数 抗CCP抗体(%) RF [M(P25, P75),U/mL] ESR [M(P25, P75),mm/h] CRP [M(P25, P75),mg/L] D-二聚体[M(P25, P75),mg/L] IgA [M(P25, P75),g/L]
    一般RA组 40 32.5(13/40) 101.14(32.24, 150.41) 28.5(14.0, 52.0) 5.0(0.0, 21.0) 0.60(0.30, 1.41) 2.46(1.69, 2.94)
    RA-ILD组 48 60.4(27/48) 148.61(110.02, 206.99) 41.5(30.0, 80.0) 26.5(4.0, 50.0) 1.44(0.72, 2.31) 3.12(2.16, 4.04)
    统计量 6.816a 2.866b 2.697b 3.464b 3.549b 2.669b
    P 0.009 0.004 0.007 0.001 <0.001 0.008
    注:a为χ2值,bZ值。
    下载: 导出CSV

    表  3  2组RA患者KL-6与IL-33水平比较[M(P25, P75)]

    Table  3.   Comparison of KL-6 and IL-33 levels between two groups of RA patients [M(P25, P75)]

    组别 例数 KL-6(U/mL) IL-33(pg/mL)
    一般RA组 40 204.70(140.85, 272.70) 18.88(6.04, 66.26)
    RA-ILD组 48 356.20(237.00,528.80) 85.89(26.81,182.92)
    Z 10.267 6.480
    P 0.001 0.011
    下载: 导出CSV

    表  4  各项血清免疫学指标对RA-ILD的诊断效能

    Table  4.   Diagnostic efficacy of various serum immunologic indices for RA-ILD

    项目 临界值 灵敏度(%) 特异度(%) 约登指数 AUC(95%CI)
    RF 97.05 U/mL 83.3 50.0 0.333 0.678(0.564~0.792)
    ESR 33.5 mm/h 72.9 60.0 0.329 0.667(0.554~0.781)
    CRP 34 mg/L 45.8 87.5 0.333 0.716(0.609~0.823)
    IgA 3.01 g/L 56.3 82.5 0.388 0.666(0.552~0.780)
    D-二聚体 0.605 mg/L 85.4 52.5 0.379 0.702(0.591~0.812)
    KL-6 300.95 U/mL 60.4 85.0 0.454 0.773(0.677~0.870)
    IL-33 81.17 pg/mL 54.2 82.5 0.367 0.705(0.596~0.814)
    KL-6和IL-33联合检测 81.9 97.4 0.793 0.816(0.730~0.901)
    下载: 导出CSV
  • [1] AKIYAMA M, KANEKO Y. Pathogenesis, clinical features, and treatment strategy for rheumatoid arthritis-associated interstitial lung disease[J]. Aut Rev, 2022, 21: 103056. DOI: 10.1016/j.autrev.2022.103056.
    [2] 梅永君, 费艳芳, 王健, 等. 类风湿关节炎相关自身抗体与并发间质性肺病的相关性研究[J]. 中华全科医学, 2020, 18(5): 720-722. doi: 10.16766/j.cnki.issn.1674-4152.001338

    MEI Y J, FEI Y F, WANG J, et al. Research on the correlation between rheumatoid arthritis-related autoantibodies and interstitial lung disease[J]. Chinese Journal of General Practice, 2020, 18(5): 720-722. doi: 10.16766/j.cnki.issn.1674-4152.001338
    [3] HUANG S, DOYLE T J, HAMMER M M, et al. Rheumatoid arthritis-related lung disease detected on clinical chest computed tomography imaging: prevalence, risk factors, and impact on mortality[J]. Semin Arthritis Rheum, 2020, 50(6): 1216-1225. doi: 10.1016/j.semarthrit.2020.08.015
    [4] WANG Y K, CHEN S Q, ZHENG S Y, et al. The role of lung ultrasound B-lines and serum KL-6 in the screening and follow-up of rheumatoid arthritis patients for an identification of interstitial lung disease: review of the literature, proposal for a preliminary algorithm, and clinical application to cases[J]. Arthritis Res Ther, 2021, 23: 212. doi: 10.1186/s13075-021-02586-9
    [5] KELLY C, MATTESON E, ARINGER M, et al. effects of nintedanib in patients with progressive fibrosing interstitial lung disease associated with Rheumatoid Arthritis(RA-ILD)in the inbuild trial annals of the Rheumatic Diseases[J]. Scie Abst, 2021, 80: 69.
    [6] WELLS A U, FLAHERTY K R, BROWN K K, et al. Nintedanibin in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo controlled, parallel-group trial[J]. Lancet Respir Med, 2020, 8(20): 453-460.
    [7] MENA-V' A N, ROJAS-GIMENEZ M, ROMERO-BARCO C M, et al. Predictors of progression and mortality in patients with prevalent rheumatoid arthritis and interstitial lung disease: a prospe-ctive cohort study[J]. Clin Med, 2021, 10: 874.
    [8] IBRAHEIM M K, GOVINDU R R. Rheumatoidarthritis associated interstitial lung di-sease[J]. Am J Med Sci, 2020, 359(5): 312-313. doi: 10.1016/j.amjms.2019.12.010
    [9] KIM H C, CHORI K H, JACOB J, et al. Prognostic role of blood KL-6 in rheuma-toid arthritis associated interstitial lung disease[J]. PLoS One, 2020, 15(3): e229997. DOI: 10.1371/journal.pone.0229997.
    [10] 吕程娜, 唐攀, 郭伦, 等. 血清标记物在类风湿关节炎相关间质性肺疾病中的作用[J]. 生命的化学, 2021, 41(1): 41-48.

    LYU C N, TANG P, GUO L, et al. Role of serum markers in rheumatoid arthritis-associated interstitial lung disease[J]. Chemistry of Life, 2021, 41(1): 41-48.
    [11] MANTOVANI A, DINARELLO C A, MOLGORA M, et al. Interleukin-1 and related cytokines in the regulation of inflammation and immunity[J]. Immunity, 2019, 50: 778-795.
    [12] CHEN Z, BOZEC A, RAMMING A, et al. Anti-inflammatory and immune-regulatory cytokines in rheumatoid arthritis[J]. Rheumatology, 2019, 15(3): 9-17.
    [13] ZHU X, ZHU J. CD4 T Helper cell subsets and related human immunological disorders[J]. J Molecu Sci, 2020, 21: 8011.
    [14] VERSACE A G, BITTO A, IOPPOLO C, et al. IL-13 and IL-33 serum levels are increased in systemic sclerosis patients with interstitial lung disease[J]. Front Med, 2022, 9: 825567. DOI: 10.3389/fmed.2022.825567.
    [15] WANG L, TANG J, YANG X, et al. TGF-β induces ST2 and programs ILC2 development[J]. Nat Commun, 2020, 11(1): 35.
    [16] ZHANG J J, QIU J X, ZHOU W Y, et al. Neuropilin-1 mediates lung tissue-specific control of ILC2 function in type 2 immunity[J]. Nat Immu, 2022, 23: 237-250.
    [17] MIKULS T R, AURAV R, THIELE G M, et al. The impact of airborn endotoxin exposure on rheumatoid arthritis-related joint damage, autoantigen expression, autoimmunity, and lung disease[J]. Inter Immun, 2021, 100: 108069. DOI: 10.1016/j.intimp.2021.108069.
  • 加载中
图(1) / 表(4)
计量
  • 文章访问数:  177
  • HTML全文浏览量:  78
  • PDF下载量:  19
  • 被引次数: 0
出版历程
  • 收稿日期:  2023-04-08
  • 网络出版日期:  2024-01-13

目录

    /

    返回文章
    返回